Chief Executive Officer

Jeffrey Brewer is founder and CEO of Bigfoot Biomedical. Since his son’s 2002 diagnosis of Type 1 Diabetes (T1D), Jeffrey has been a thought leader and influencer in the diabetes community, first as a philanthropist who funded and launched the Artificial Pancreas Project along with JDRF Intl., then as JDRF’s CEO where he forged partnerships with industry to drive medical device innovation in diabetes. Jeffrey spearheaded US regulatory reform and elevated JDRF’s strategic priorities to include healthcare policy, reimbursement, and technology access. Previous to his work in diabetes, Jeffrey was an active entrepreneur where he founded and led highly successful dot-com start-ups including CitySearch and Overture /

“People with diabetes don’t want another feature on a pump. They want a different way of living.”




Before founding Bigfoot, Bryan previously led a successful career in quantitative finance, first as management in one of the world’s largest securities trading institutions, and subsequently as an entrepreneur, where he founded and led a fully automated trading company. Since his son’s diagnosis with T1D in 2011, Bryan has focused his efforts in the diabetes technology space where he invented algorithms for predicting glucose values and automating insulin delivery. His wife and son, both of whom have T1D, have benefited over the past four years from the use of a proof of concept device that he created to automate their insulin delivery. This is the first real-world demonstration of successful use of adaptive insulin delivery algorithms in pediatric and adult settings over an extended period of time. time.

“For the four years that my family has used the first system I created, diabetes has been so much easier to manage that it's like a different disease."



Chief Financial Officer

Brett has over 20 years of experience as a financial professional, more than 15 of which have been in the medical device sector. Brett's strong finance and operations background in life science and medical device provide increased depth and breadth to the management team. He has experience in a range of different environments ranging from startups through established profitable businesses. Brett has served as the CFO at Cardiokinetix, Inc., Vibrynt, Inc., and Concentric Medical, Inc. Prior to his tenure as CFO for these organizations, Brett held the positions of Sr. Director of Finance & Administration at Concentric Medical, Inc. and Corporate Controller at Emphasys Medical. He spent five years at Guidant Corporation (now Boston Scientific) in strategic planning, sales finance, financial planning, and internal audit, as well as serving as Assurance Manager at PricewaterhouseCoopers in Chicago. Brett holds a B.S. in Accounting and an M.B.A. from Indiana University and is also a Certified Public Accountant.


Ian Hanson

Chief Technology Officer

Ian has 20 years of experience in device development with particular expert proficiency in drug delivery systems. He comes most recently from Unilife, where he served as Senior Vice President and Chief Operating Officer and led the development of their wearable injector platform and advanced drug delivery systems. Prior to Unilife, Hanson held senior leadership roles with Medtronic Diabetes where he created their Advanced and Systems Engineering Department and was responsible for development and commercialization of insulin delivery devices and diabetes management systems for over a decade. Through his almost 11 years with Medtronic, he gained exceptional product development acumen, especially with respect to the rigor required of regulated technologies.

Jyoti Palaniappan

Chief Commercial Officer

Jyoti comes to Bigfoot with over 20 years of commercial leadership experience and over 11 years serving the diabetes medical device sector. As Chief Commercial Officer, Palaniappan brings a wealth of experience in product management, product launch strategy, marketing, sales, customer care, business development, and reimbursement, in both US and global contexts. Jyoti spent the last eleven years at Abbott in the diabetes care unit serving in executive commercial roles. He first held sales and marketing leadership roles in the U.S. commercial operations where he had responsibility for market access, healthcare professional, consumer, and pharmacy & DME channels. Most recently, Jyoti served in a strategic leadership role in the Global commercial operations where he supported Abbott’s market defining launch for FreeStyle Libre. Prior to Abbott, he led global and US commercial organizations for Thermo Fisher Scientific in the field of genomics. Earlier in his career, Jyoti provided strategic consulting services at McKinsey & Company in the areas of sales & marketing, product launch, and corporate strategy. He holds a B.S. in Biology from University of Michigan and an M.B.A & M.P.H. from Emory University.


Chief of Staff

John is the co-founder and former CEO of Patients Pending LTD - a company that has helped hundreds of thousands of people with diabetes live simpler, safer and more balanced lives with its smart cap for insulin pens, Timesulin. John created the Timesulin solution based on his own challenges in managing his own Type 1 diabetes, which he was diagnosed with just before his fourth birthday. As a thirty-plus-year diabetes veteran, this condition has never prevented John from living his life fully - he has participating in the world’s longest cross-country ski race, completing multiple triathlons and endurance races and lived on four different continents. John is an international speaker on the topic of living with diabetes and was recognized as one of the Ten Outstanding Young Persons of the Year 2012 in Sweden and a finalist for Novo Nordisk & Lyfebulb Patient Entrepreneur award in 2017. Prior to founding Timesulin John was a Business Director with Acceleration (acquired by marketing giant WPP in 2012), a leading provider of digital marketing services for the publishing and advertising industries. Between 2005 and 2010 John moved between their offices in Cape Town, New York, and London and his portfolio included some of the world’s biggest consumer and business brands. He launched Patients Pending in 2011 and it was acquired by Bigfoot Biomedical in June 2017 as part of its entrance into the connected smart insulin pen space.


VP, Clinical and Medical Affairs

Jen brings twenty years of experience in diabetes care and clinical research.  As a Nurse Practitioner and Certified Diabetes Educator, Jen has worked to empower people to live well with diabetes. Jen spent over 15 years working as a research coordinator for clinical trials primarily focused on novel diabetes devices including continuous glucose monitors, and a myriad of artificial pancreas systems at Stanford University Medical Center. Jen is passionate about the translation of experience gained in clinical research into advances in clinical care and education. Prior to joining the team at Bigfoot Biomedical, Jen served as a consultant to a number of diabetes care companies and organizations, including Tandem, Insulet, Dexcom, Becton Dickinson, Abbott Diabetes Care, Unomedical, and Lifescan. Jen leverages her experience in education, clinical care, research, and industry to find innovative ways to evaluate novel therapies, improve diabetes care, and reduce the burdens of diabetes for everyone whose life is touched by this challenging disease.


VP, Regulatory & Quality

Kate brings nearly 10 years experience in Regulatory and Quality Affairs and more than 20 years experience in medical device development. Most recently Kate provided her expertise in Regulatory and Quality Affairs as a consultant to a variety of companies in the cardiovascular and diabetes spaces covering a range of topics, including Q-Submissions and FDA meetings, recall reporting, QMS changes and Notified Body audit responses. Prior to consulting, Kate served as Senior Director of Regulatory Affairs at Hansen Medical, responsible for all regulatory activities, encompassing multiple 510(k)s and devices with 513(i)1(e) labeling restrictions. During her ten year tenure, she established excellent relationships with the FDA Cardiovascular Branch and successfully negotiated a pivotal trial design from an RCT to an OPG with an adaptive statistical design. Kate spent the first part of her career in R&D, developing and later leading teams in the development of innovative devices in the cardiovascular, vascular, and gastrointestinal arenas. Kate earned a Master’s degree in Smart Product Design from Stanford and a Bachelor’s degree in Mechanical Engineering from Harvard.


VP, Human Resources

Lynn brings over 20 years of human resource and high volume recruiting experience building emerging growth technology companies throughout Silicon Valley. Lynn has held executive roles with a keen focus on high-quality rapid growth by aligning recruiting, compensation, benefit, and organizational strategies to achieve these aggressive growth plans with such companies as Netscape, Calico Commerce, and Sybase. Lynn also brings several years as an executive search consultant with DHR International where she led several leadership searches in the technology, nonprofit and educational sectors. Lynn’s daughter was diagnosed with T1D when she was 11 years old.
Lane Desborough


Chief Engineer

Lane spent twenty years creating customer and business value at Honeywell, GE,  and Medtronic in the areas of lean product development, data science, modeling & simulation, automation, human factors, and system safety engineering. His experience implementing and remotely monitoring control systems in industrial plants enabled him to jump immediately into the fight against  T1D when his son was diagnosed in 2009. Lane joined Medtronic Diabetes in 2010, led the commercialization of Predictive Low Glucose Management, and was subsequently promoted to Chief Engineer, Insulin Delivery/Closed Loop. In 2013 Lane co-­developed Nightscout, a free/open source CGM remote monitoring system, now used by thousands of families. His worldwide volunteer and outreach work has expanded his perspective on the diabetes challenges faced by families, healthcare professionals, and payers.